Astrazeneca (AZN) Net Cash Flow (2018 - 2026)

Astrazeneca has reported Net Cash Flow over the past 16 years, most recently at $2.8 billion for Q1 2026.

For Q1 2026, Net Cash Flow rose 420.63% year-over-year to $2.8 billion; the TTM value through Mar 2026 reached $6.6 billion, up 311.83%, while the annual FY2025 figure was $4.4 billion, 11.04% up from the prior year.
Net Cash Flow for Q1 2026 was $2.8 billion at Astrazeneca, up from -$1.5 billion in the prior quarter.
Over five years, Net Cash Flow peaked at $3.2 billion in Q2 2025 and troughed at -$1.5 billion in Q4 2025.
A 5-year average of $930.4 million and a median of $639.5 million in 2023 define the central range for Net Cash Flow.
Biggest five-year swings in Net Cash Flow: crashed 216.06% in 2022 and later skyrocketed 2173.57% in 2025.
Year by year, Net Cash Flow stood at $945.0 million in 2022, then dropped by 21.59% to $741.0 million in 2023, then soared by 178.68% to $2.1 billion in 2024, then plummeted by 172.01% to -$1.5 billion in 2025, then skyrocketed by 288.37% to $2.8 billion in 2026.
Business Quant data shows Net Cash Flow for AZN at $2.8 billion in Q1 2026, -$1.5 billion in Q4 2025, and $2.2 billion in Q3 2025.

Peer Comparison